Search clinical trials for: Tiotropium/Salmeterol

Total 734 results

Boehringer Ingelheim

Completed

Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim
Pfizer

Completed

Randomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.

Asthma

Austria, Germany, Ukraine
Boehringer Ingelheim

Completed

Pharmacokinetics of Salmeterol (Serevent®) After Inhalation With Metered Dose Inhaler (MDI) and Diskus® in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Austria, Canada, Germany, Netherlands, Russian Federation, Sweden
Boehringer Ingelheim

Completed

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Australia, Austria, Belgium, Canada, Chile, Germany, Italy, New Zealand
Imperial College London
Boehringer Ingelheim

Completed

Airway Effects of Tiotropium in Patients With COPD

COPD | LUNG DISEASES, OBSTRUCTIVE

United Kingdom
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Tiotropium in Cystic Fibrosis Patients

Cystic Fibrosis
GlaxoSmithKline

Completed

A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD). (ADC111114)

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Denmark, Finland, France, Georgia, Germany, Greece, Guatemala, Hungary, India, Ireland, Israel, Italy, Korea, Republic of, Latvia, ... and more
Novartis Pharmaceuticals

Withdrawn

Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control (INITIATE)

Chronic Obstructive Pulmonary Disease (COPD)
Verona Pharma plc

Completed

The Effects of RPL554 in Addition to Tiotropium in COPD Patients

Chronic Obstructive Pulmonary Disease Moderate
Boehringer Ingelheim

Completed

Pharmacokinetics of Salmeterol Via HandiHaler® in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Canada, Finland, France, Germany, Hungary, Italy, Spain, United Kingdom
Orion Corporation, Orion Pharma

Completed

Inspiratory Flow Parameters With Placebo Easyhaler and Placebo HandiHaler (TIOPIF)

Healthy Volunteer | COPD

Estonia
GlaxoSmithKline

Withdrawn

Shortness Of Breath Questionnaire Validation Study

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Canada, Germany, Netherlands, Sweden
Boehringer Ingelheim

Completed

Evaluation of the Lung Deposition Rate and Distribution Pattern of Tiotropium Via HandiHalerTM in Healthy Subjects and Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline

Completed

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Argentina, Germany, Russian Federation, Ukraine, United States, South Africa, Korea, Republic of, Romania, Canada, France, Italy, Chile, Denmark
Boehringer Ingelheim
Pfizer

Completed

Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma

Asthma

United States, Argentina, Australia, Bulgaria, Germany, Guatemala, Hungary, Israel, Latvia, Mexico, Philippines, Portugal, South Africa, Ukraine
Boehringer Ingelheim
Pfizer

Completed

Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma

Asthma

United States, Germany, Latvia, Lithuania, Slovenia
Boehringer Ingelheim

Completed

Salmeterol Inhalation Powder Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Theravance Biopharma
Viatris Inc.

Completed

Phase 4 COPD and Suboptimal Inspiratory Flow Rate (PIFR-2)

Chronic Obstructive Pulmonary Disease

United States
AstraZeneca

Completed

Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
Boehringer Ingelheim

Completed

Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States, Belgium, Canada, Denmark, Germany, Hungary, Netherlands
Peking University People's Hospital
First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine

Unknown

Yiqi Huoxue Huatan Granule for Reducing Mortality in COPD With Chronic Respiratory Failure

Chronic Obstructive Pulmonary Disease | Chronic Respiratory Failure

China
Novartis Pharmaceuticals

Completed

A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator

COPD

China
Boehringer Ingelheim

Completed

A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

China
Boehringer Ingelheim

Completed

Early Intervention Efficacy in COPD

Pulmonary Disease, Chronic Obstructive

Japan
Verona Pharma plc
Iqvia Pty Ltd; LGC Limited

Completed

Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD

COPD

United States
Guangzhou Institute of Respiratory Disease
Boehringer Ingelheim

Recruiting

Effect of Tiotropium Bromide Combined With Odaterol on Small Airway Remodeling in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

China
Boehringer Ingelheim
Pfizer

Completed

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma

Asthma

United States, Argentina, Australia, Belgium, Brazil, Canada, Czech Republic, Germany, Guatemala, Hungary, Latvia, Lithuania, Poland, Romania, Russian Federation, Slovakia, Ukraine
Neovii Biotech
Fresenius Biotech North America

Completed

Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy

Ovarian Cancer

United States
Boehringer Ingelheim

Completed

Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Australia, Bulgaria, Canada, China, Czech Republic, Denmark, Estonia, Finland, France, Germany, Guatemala, Hungary, India, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Portugal, Russian... and more
Boehringer Ingelheim
Pfizer

Completed

Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma

Asthma

Argentina, Austria, Croatia, Estonia, Guatemala, Hungary, India, Italy, Korea, Republic of, Latvia, Poland, Slovakia
Boehringer Ingelheim
Pfizer

Completed

Comparison of Two Daily Dose Regimens of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for 4 Weeks on Top of Maintenance Therapy With Inhaled Corticosteroid Controller Medication

Asthma

Austria, Germany, Hungary, Slovenia
Boehringer Ingelheim
Pfizer

Completed

A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma

Asthma

Austria, Czech Republic, Estonia, Germany, Latvia
McMaster University
Boehringer Ingelheim

Completed

Study to Evaluate the Effects of Tiotropium Bromide on Chronic Obstructive Pulmonary Disease (COPD) During Exercise

COPD
Teva Branded Pharmaceutical Products R&D, Inc.

Withdrawn

A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease | COPD
Boehringer Ingelheim

Completed

Acute Bronchodilator Response of a Single Dose of Atrovent or Berotec on Top of Pharmacodynamic Steady State of Spiriva

Pulmonary Disease, Chronic Obstructive

Netherlands
Boehringer Ingelheim

Completed

A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Netherlands, Denmark, France, South Africa, Austria, Belgium, Sweden
Novartis Pharmaceuticals

Completed

A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149

Chronic Obstructive Pulmonary Disease

China, Argentina, Taiwan, Chile
Boehringer Ingelheim
Pfizer

Completed

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma

Asthma

United States, Bulgaria, Canada, Germany, Guatemala, Hungary, Korea, Republic of, Latvia, Lithuania, Norway, Portugal, Romania, Russian Federation, Sweden, Ukraine, United Kingdom
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Austria, Belgium, Brazil, Canada, China, Colombia, Croatia, Germany, Hungary, India, Ireland, Japan, Norway, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Sweden, Taiwan, Turkey, United Kingdom
Boehringer Ingelheim
Pfizer

Completed

Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma

Asthma

United States, Chile, Germany, Hungary, Italy, Korea, Republic of, Latvia, Mexico, Russian Federation, Slovakia, Spain, Ukraine
Orion Corporation, Orion Pharma

Completed

Comparison of Tiotropium Absorption From Tiotropium Easyhaler and Spiriva HandiHaler (TEMPO)

Healthy Volunteers

Finland
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers (BREATH-PK500)

Bioequivalence

Greece
University of Dundee

Completed

Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma (CLE001)

Asthma

United Kingdom
GlaxoSmithKline

Completed

Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate

Asthma

United States, Peru, Kenya, Puerto Rico
GlaxoSmithKline

Completed

Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations

Pulmonary Disease, Chronic Obstructive

United States, Canada

3

Subscribe